ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

23 links0 made here, not in the record38 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT03872947A Study of TRK-950 inCombinations WithAnti-Cancer TreatmentRegimens in Patients WithAdvanced Solid TumorsToray Industries, IncPhase 1 · completedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 8 · ClinicalTrials.gov record · Version of 2026-10-08Version of 2026-10-08CONDITIONSColorectal NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionCholangiocarcinomaThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termUrinary Bladder NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termOvarian NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedStomach NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termCarcinoma, Renal CellThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termMelanomaThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termCarcinoma, Ovarian Epitheli…The registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termFallopian Tube NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termDRUGSTRK-950Intervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedIrinotecanIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundLeucovorinIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundFluorouracilEntry “5-FU”, read by our name rule›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundGemcitabineIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCisplatinIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCarboplatinIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundRamucirumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPaclitaxelIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundNivolumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerPembrolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundImiquimodEntry “Imiquimod Cream”, read by our …›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundBevacizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundLiposomal doxorubicinEntry “PLD”, read by our name rule›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

TRK-950

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “TRK-950”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Oct 8The record itselfClinicalTrials.gov recordVersion of 2026-10-08Record change
Nov 2TRK-950Claude Opus 5.5TestedCurrent
Nov 2IrinotecanClaude Opus 5.5BackgroundCurrent
Nov 2LeucovorinClaude Opus 5.5BackgroundCurrent
Nov 2FluorouracilClaude Opus 5.5BackgroundCurrent
Nov 2GemcitabineClaude Opus 5.5BackgroundCurrent
Nov 2CisplatinClaude Opus 5.5BackgroundCurrent
Nov 2CarboplatinClaude Opus 5.5BackgroundCurrent
Nov 2RamucirumabClaude Opus 5.5BackgroundCurrent
Nov 2PaclitaxelClaude Opus 5.5BackgroundCurrent
Nov 2NivolumabClaude Opus 5.5Background · partnerCurrent
Nov 2PembrolizumabClaude Opus 5.5BackgroundCurrent
Nov 2ImiquimodClaude Opus 5.5BackgroundCurrent
Nov 2BevacizumabClaude Opus 5.5BackgroundCurrent
Nov 2Liposomal doxorubicinClaude Opus 5.5BackgroundCurrent
Nov 14Colorectal NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14CholangiocarcinomaRule based · condition-kind ruleFinest filed termCurrent
Nov 14Urinary Bladder NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Ovarian NeoplasmsRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 14Stomach NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Carcinoma, Renal CellRule based · condition-kind ruleFinest filed termCurrent
Nov 14MelanomaRule based · condition-kind ruleFinest filed termCurrent
Nov 14Carcinoma, Ovarian EpithelialRule based · condition-kind ruleFinest filed termCurrent
Nov 14Fallopian Tube NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 18TRK-950Rule based · role ruleTestedAgrees
Nov 18IrinotecanRule based · role ruleBackgroundAgrees
Nov 18LeucovorinRule based · role ruleBackgroundAgrees
Nov 18FluorouracilRule based · role ruleBackgroundAgrees
Nov 18GemcitabineRule based · role ruleBackgroundAgrees
Nov 18CisplatinRule based · role ruleBackgroundAgrees
Nov 18CarboplatinRule based · role ruleBackgroundAgrees
Nov 18RamucirumabRule based · role ruleBackgroundAgrees
Nov 18PaclitaxelRule based · role ruleBackgroundAgrees
Nov 18NivolumabRule based · role ruleBackgroundAgrees
Nov 18PembrolizumabRule based · role ruleBackgroundAgrees
Nov 18ImiquimodRule based · role ruleBackgroundAgrees
Nov 18BevacizumabRule based · role ruleBackgroundAgrees
Nov 18Liposomal doxorubicinRule based · role ruleBackgroundAgrees
As of nowColorectal NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.